Seeking Alpha
View as an RSS Feed

Bret Jensen  

View Bret Jensen's Articles BY TICKER:
A, AA, AAPL, AAWW, ABB, ABBV, ABT, ABTL, ABX, ACET, ACLS, ACMP, ACTG, ACTV, ADBE, ADSK, AEP, AER, AGCO, AGEN, AGU, AHH, AHT, AIG, AKS, ALJ, ALL, ALR, AMAT, AMFW, AMGN, AMKR, AMTD, AMZG, AMZN, ANF, ANIK, ANV, APA, APC, APEI, APL, ARCP, ARII, ARLP, ARO, ARP, ASH, ATRS, ATSG, ATU, ATVI, ATW, AU, AVGO, AVNR, AXAS, AXTI, AYR, AZN, BA, BAC, BAS, BAX, BBBY, BBEP, BBRY, BBT, BBW, BBY, BCEI, BGC, BGFV, BHI, BIDU, BIG, BIIB, BIOL, BK, BKCC, BKH, BLK, BMO, BMR, BNS, BP, BRCD, BRCM, BRKS, BTU, BWP, BX, BYI, C, CALL, CARB, CAT, CBI, CBOU, CDE, CELG, CEO, CERS, CGIX, CGR, CHK, CHKP, CHL, CHMT, CJES, CKSW, CLDT, CLF, CLMT, CLR, CMG, CMI, CMLP, CNAT, CNDO, CNP, CNQ, CNQR, CNX, COF, COG, COH, COOL, COP, CORT, COV, CPE, CPIX, CPNO, CPSI, CRM, CROX, CRUS, CRZO, CSCO, CSX, CTCM, CVE, CVS, CVX, CXPO, CXS, CY, DAKT, DAN, DD, DDE, DE, DECK, DELL, DENN, DG, DIS, DK, DNR, DO, DOW, DPM, DRH, DRIV, DSCO, DTLK, DTV, DUSA, DVAX, DVN, DVR, DWA, DXLG, DY, E, EBAY, ECA, ECPG, EDR, ELY, EMC, END, ENDP, EOG, EOX, EPAM, EPAX, EPB, EPD, EPIQ, EPR, EQM, EROC, ESIO, ESV, ETE, ETN, ETP, ETRM, EVEP, EWZ, EXK, EXLP, EXXI, F, FANG, FB, FCH, FCX, FDX, FIG, FLL, FLR, FLY, FOLD, FOSL, FRD, FSC, FSII, FST, FURX, FXCM, GA, GBX, GCOM, GD, GE, GEF, GEL, GEOY, GERN, GES, GEVA, GFI, GILD, GLP, GLUU, GLW, GM, GNMK, GNW, GOLD, GOOG, GOOGL, GPOR, GPS, GS, GSK, GSM, GSS, GTATQ, GTE, HAL, HAR, HBM, HCLP, HEP, HERO, HES, HFC, HIG, HK, HL, HLF, HLX, HMA, HON, HOS, HP, HPQ, HPT, HRS, HRZN, HTA, HTGC, HTLF, HURN, HZNP, IACI, IAG, IGTE, INN, INT, INTC, INVN, IO, IP, IPGP, IQNT, IRDM, IRET, IRT, ISRG, ISSI, ITRI, ITT, IVAC, IVAN, JAZZ, JDSU, JEC, JNJ, JNPR, JOY, JPM, KBH, KBR, KCAP, KDN, KEG, KERX, KEYN, KFY, KKR, KLAC, KLIC, KO, KOG, KONA, KR, KRA, KRG, KRO, LAD, LCI, LGCY, LIFE, LIME, LINE, LLL, LLNW, LLY, LMOS, LMT, LNCO, LNKD, LO, LOCO, LOW, LPRI, LPX, LRE, LSI, LUK, LULU, LVS, LXP, LYB, M, MAN, MANT, MCEP, MCGC, MCHX, MCP, MDR, MDT, MEI, MELI, MEMP, MET, MHR, MIND, MITL, MMLP, MMP, MNK, MO, MOD, MOS, MPC, MPO, MPW, MRCY, MRGE, MRK, MRO, MRVL, MS, MSFT, MT, MTDR, MTOR, MTSN, MU, MUR, MXIM, MYL, MYRG, NAVB, NBL, NBR, NCT, NE, NEE, NEM, NEON, NFLX, NFX, NGLS, NIHD, NILE, NOG, NOK, NOV, NPTN, NR, NSC, NSPH, NTAP, NTSP, NUAN, NVAX, NVDA, NVS, NWY, NXPI, NYCB, NYX, OAK, OAS, OCN, OCZ, OHAI, OHI, OI, OIS, OKS, OME, OPLK, ORAN, ORBK, ORCL, ORIG, ORLY, OUTR, OVTI, OXY, OZM, PAA, PAAS, PACD, PACR, PANW, PAYX, PBF, PBH, PBI, PBY, PCLN, PCTI, PDH, PDLI, PDS, PEET, PEG, PES, PETM, PETS, PFE, PFMT, PGEM, PH, PKT, PKY, PLAB, PM, PNC, PNG, PNK, PNRA, POM, POT, PRTA, PRU, PSX, PTEN, PTX, PULB, PVR, PWER, QCCO, QCOM, QLGC, QLTY, QRE, QRVO, QSR, QUMU, R, RAIL, RAX, RCL, RDC, RDWR, REGN, RES, REXX, RF, RHI, RHT, RIG, RIGL, RIO, RNET, RNN, ROC, ROSE, ROVI, RPRX, RPTP, RRD, RSTI, RTEC, RTN, RUE, RUTH, RVBD, SAM, SARA, SBRA, SCLN, SCMR, SD, SDRL, SEAC, SFY, SGY, SHOR, SIGA, SIMG, SIMO, SIRI, SKUL, SLB, SLCA, SLTM, SLW, SM, SMCI, SN, SNH, SNY, SODA, SPLK, SPLS, SPN, SPPI, SPRT, SPY, SQNM, SSH, SSNLF, STI, STJ, STKL, STMP, STO, STT, STX, SUNE, SVU, SWFT, SWKS, SYMC, SYNA, SYPR, SYRG, SYY, T, TAL, TAP, TBT, TC, TCAP, TDW, TEF, TER, TESO, TEVA, TEX, TGX, TICC, TIVO, TKR, TLLP, TLM, TMO, TOT, TPC, TPLM, TRLG, TRN, TRP, TSLA, TSO, TST, TSYS, TTI, TWC, TWI, TWO, TWX, UA, UNH, UNIS, UNT, UPL, URI, USB, V, VALE, VELTF, VICL, VLO, VMW, VNR, VOD, VRA, VSEC, VXX, VZ, WAC, WBA, WDC, WEN, WFC, WFT, WHR, WIFI, WLL, WMT, WRES, XEC, XOM, XRX, YELP, YHOO, Z, ZAGG, ZEUS, ZIXI, ZLTQ, ZNGA
  • 2 Attractive Small-Cap Biotech Stocks On The Verge Of Breakouts
    Tue, Feb. 24 AGEN, ZGNX 25 Comments

    Summary

    • The small cap biotech & biopharma spaces are inherently volatile but have delivered huge winners to my portfolio over the past six months.
    • I believe in building a well-diversified portfolio by taking small stakes across a myriad of promising concerns to help mitigate risk in these high beta sectors.
    • Two of those attractive equities are profiled below. Both have had recent positive catalysts and the stocks look poised to break out and head significantly higher.
  • AbbVie: Attractive Valuation, Growth Prospects & Yield
    Tue, Feb. 24 ABBV 33 Comments

    Summary

    • It is getting harder to find bargains in the market that now trades at ~18 times trailing earnings with negative earnings growth predicted for the first quarter year-over-year.
    • However, I am still finding good value in some of the larger biotech & biopharma names especially those trading at a discount to the overall market multiple.
    • One of these is AbbVie which offers investors the "troika" of attractive features including solid valuations, good growth prospects and one of the highest yields iwithin biopharma.
  • Chicago Bridge & Iron: Coming Back From The Brink
    Thu, Feb. 19 CBI 102 Comments

    Summary

    • The stock of Chicago Bridge & Iron has been one of the worst performing in the market over the prior nine months.
    • However, the stock has bounced significantly in recent weeks as sentiment seems to be turning on these beaten down shares.
    • This could be a great entry point for long term value investors as the stock has picked up a key fan, is cheap and has further upside.
  • Celgene: Still An Attractive Core Growth Play
    Wed, Feb. 18 CELG 11 Comments

    Summary

    • Earnings growth is getting hard to come by in this market, with earnings growth currently in the low-single digits year over year during this earnings season.
    • Some of the larger biotech stocks offer a great combination of value and solid growth prospects and are an oasis for earnings-starved investors.
    • One of these core large-cap biotech stocks is Celgene whose shares still offer good value even after tripling in price over the past couple of years.
  • The Market Is Not Cheap
    Mon, Feb. 16 DIA, SPY, QQQ 56 Comments

    Summary

    • The market has rallied recently as equities have erased all of their losses in January and most indices stand at all time highs.
    • This rally has occurred despite earnings estimates for the overall market falling significantly over the past six weeks.
    • The U.S. remains the "best house in a bad neighborhood" but valuations look stretched here and investors should prepare for a three to five percent decline in the overall market.
  • Gilead: No Reason To Panic Here
    Fri, Feb. 13 GILD 166 Comments

    Summary

    • The shares of biotech juggernaut Gilead Sciences have been under pressure recently due to concerns of expanded discounted pricing within its hepatitis C franchise.
    • This has overshadowed the company's recent blow out earnings and the announcement of a massive stock buyback program.
    • Lower prices will also beget a much larger prescription base offsetting the impacts of discounts significantly. Investors are being given a great entry point to buy this cheap biotech stock.
  • Las Vegas Sands: High Yielder Has Put In A Bottom
    Tue, Feb. 10 LVS 22 Comments

    Summary

    • High yielding Las Vegas Sands had a rough 2014 as a crackdown on corruption by new leadership in China led to the worst year for Macau gambling in over decade.
    • The stock recently appears to have bottomed and the shares appear to be oversold. The stock is setting up for a nice risk/reward story in 2015.
    • The company recently substantially boosted its dividend payouts and stock buyback programs and the stock now yields over 4.5%.
    • Although growth in Macau may not return tomorrow or next month, the company is well positioned for long-term growth in Asia and the dividend pays an investor to wait.
  • General Motors: On A Real Roll To Start 2015
    Mon, Feb. 9 GM 22 Comments

    Summary

    • General Motors after spending most of 2014 sputtering due to a major recall scandal has started out 2015 on much stronger footing.
    • The American manufacturing icon delivered a huge earnings beat and also boosted its already generous dividend payout by 20%.
    • The domestic auto market remains robust and lower gasoline prices have meant more sales of higher margin trucks and SUVs. Why this rally could continue for quite a while is explained below.
  • Gilead: Long-Term Investors Should Buy Any Dip
    Thu, Feb. 5 GILD 128 Comments

    Summary

    • Biotech juggernaut Gilead Sciences delivered one of the best earnings reports of the quarter after the bell on Tuesday.
    • Not only did the company beat both the top and bottom line consensus by a good margin; it also announce a large buyback and initiated its first dividend.
    • The stock is up more than 150% over the past two years. Despite rally, this Blue Chip Gem remains one of the cheapest large cap growth stocks in the market.
  • Where To Find Yield In February
    Mon, Feb. 2 ABBV, CLDT 13 Comments

    Summary

    • 10 year treasury yields have plunged to under 1.7% and 30 year treasury yields are at record lows. Negative interest rates exist in much of Europe.
    • Combined with stretched valuations in traditional high yield sectors like Utilities and Consumer Staples, income investors are hard pressed to find acceptable yield at reasonable values.
    • Below are a couple of ideas that pay better than three percent yields, have solid growth prospects and are attractively priced for income investors.
  • 2 Biotech Juggernauts That Belong In Every Growth Portfolio
    Sat, Jan. 31 BIIB, CELG 29 Comments

    Summary

    • The market has had a rough start to 2015 as the overall market has dropped some three percent in January as earnings estimates continue to be revised downward.
    • One sector that has held up well in this downdraft is the large cap biotech space which makes sense given earnings growth here is still robust and not softening.
    • Below are two biotech juggernauts that just reported excellent quarterly numbers and belong in every long term growth portfolio.
  • Boeing To Bound Higher Over Time
    Thu, Jan. 29 BA 24 Comments

    Summary

    • Boeing reported standout results Wednesday morning in what has been a very challenging environment for American multinationals this earnings season.
    • The company now has half a trillion order backlog; enough to sustain it for over five years even it received no new orders for a half-decade.
    • The stock should be a long term core holding for large cap growth investors. The stock is selling at a slight discount to the market and has a solid yield.
  • Not Even Apple Can Save This Market
    Thu, Jan. 29 SPY, DIA, QQQ 69 Comments

    Summary

    • Despite blow out earnings from Apple and other Fortune 500 companies on Wednesday, the market posted its second day of deep declines as volatility continue to increase.
    • Three main factors caused equities to sell off; the continued collapse of oil prices, comments from the Federal Reserve and once again Greece.
    • The market continues to feel like it is at a major inflection point and until these issues get resolved investors could be in for a rocky start to 2015.
  • Do You Believe Me Now?
    Tue, Jan. 27 DIA, SPY, QQQ 256 Comments

    Summary

    • For many months I have become less and less sanguine on the prospects for the market to continue its long rally which I have articulated many times recently.
    • It is appearing more and more this pessimistic outlook is not only warranted but more prudent by the day.
    • The market is starting to wake up to the negative impacts of a strong dollar, a collapse in oil prices, tepid global growth prospects and overly optimistic earnings estimates.
    • Equities feel overdue for a significant pull back if not an outright correction. Investors should pay heed and error right now to the side of caution.
  • Greece, 'Europe's Argentina', Strikes Again
    Mon, Jan. 26 IBM, FXE, UUP 31 Comments

    Summary

    • The story of the day are the election results in Greece which had the result of installing the far left Syriza party in power.
    • Although not as dire as this would have been several years ago, these election results will have impacts to global currencies and markets.
    • What I think this means for global markets and some investable ideas off these events are profiled below.
  • Valero Now Belongs In An Income And Value Portfolio
    Sun, Jan. 25 VLO 59 Comments

    Summary

    • One of the few sectors within the energy complex that has held up well in the market in the face of plunging crude has been the refinery space.
    • Valero Energy is the largest domestic refinery company and my pick within the sector for long-term value and income investors.
    • The company is extremely well positioned for the long term, the stock is cheap and now with an over 3% dividend yield can go into an income portfolio as well.
  • 3 Attractive Biotech Picks For 2015
    Fri, Jan. 23 CRIS, GILD, EGRX 42 Comments

    Summary

    • The biotech sector has outperformed the overall market over the past couple of months, and has been one of the stronger areas within equities during that time frame.
    • There are myriad reasons for this development, which I expect to continue over the near term, as the sector has some outstanding growth prospects.
    • Below I offer up three selections that should thrive within a well-diversified biotech/biopharma portfolio in 2015.
  • Market At Its First Major Inflection Point Of 2015 - Final Chapter
    Wed, Jan. 21 AAPL, AGEN, DIA 21 Comments

    Summary

    • Over the past two days we have taken a look at the key factors deriving the market down to begin 2015 and some reasons investors should remain optimistic.
    • Today we look at some stocks and sectors that should outperform the overall market in the New Year regardless of whether bulls or bears win this current tug of war.
    • These picks include the easiest single stock decision in the market, some plays in the strongest area of the REIT space and a shout out to some biotech selections.
  • Market At Its First Major Inflection Point Of 2015 - Part II
    Tue, Jan. 20 SPY, DIA, QQQ 25 Comments

    Summary

    • In the second of a three part series we take a look at the key drivers that should keep the market from a deep sell-off even as volatility increases.
    • Among these factors are the United States remains the best house in a bad neighborhood and the lack of investable alternatives.
    • Why domestic economic growth should improve and equities should continue to bump along despite stretched valuations and other worries detailed below.
  • Market At Its First Major Inflection Point Of 2015 - Part I
    Mon, Jan. 19 DIA, SPY, QQQ 115 Comments

    Summary

    • It has been a tough beginning of 2015, as volatility has increased markedly, driving stocks down four percent from recent highs.
    • There are three key factors driving the market lower that should be watch items for investors as we go through the next few months in the market.
    • In the first of a three-part series, we will look at these headwinds and what impacts they are having on equities in the new year.
  • My Predictions For 2015 - Final Chapter
    Mon, Jan. 12 AAPL, AGEN, DVAX 40 Comments

    Summary

    • In the final segment of a three part series on predictions for the New Year, we will take a look at some specific stocks that should outperform the market.
    • Investors should tilt their portfolios towards domestic concerns as well as large cap growth stocks selling at attractive valuations.
    • Below are some attractive picks within the biotech, technology and industrial sectors that should have very solid years in 2015.
  • Ford Starts The New Year Off Right
    Fri, Jan. 9 F 42 Comments

    Summary

    • After having a very challenging 2014, Ford is looking at much brighter days in 2015 as new models roll out and earnings ramp up again in the New Year.
    • The company just announced a 20% dividend hike and saw year-over-year growth in China of just under 20 percent.
    • The shares offer a rare combination of value, solid growth prospects in 2015 and now an almost four percent yield as well.
  • Gilead Fires Back
    Wed, Jan. 7 GILD 128 Comments

    Summary

    • The stock of Gilead Sciences was bolstered Monday despite the rout in equities by a new deal to be the preferred vendor in the Hep C space with CVS Health.
    • This is solid first step in firing back at Express Scripts which recently granted exclusive rights to AbbVie for treating some forms of hepatitis C in its network.
    • That announcement caused the stock of Gilead Sciences to decline some 20% and offered investors a great entry point on this cheap long term growth stock in biotech.
  • Agenus: A Speculative But Attractive $4 Small Cap Gem
    Sat, Jan. 3 AGEN 60 Comments

    Summary

    • To start off the New Year, I offer up a deep dive on a small, speculative, but attractive $4/share biotech stock named Agenus Inc.
    • The share price of this biotech firm has been on the move recently, as several positive catalysts have come to the forefront.
    • The stock has many of the traits I like to see in this inherently volatile space, and if things fall into place, the stock could have a great 2015.
  • Morgan Stanley Provides Some Sage Words On Gilead Sciences
    Dec. 30, 2014 GILD 102 Comments

    Summary

    • The shares of biotech juggernaut Gilead Sciences are bouncing nicely off recent declines in the start of a holiday shortened trading week.
    • Fueling the rally are some positive analyst comments and some realistic perspective on the true impact of new competition from AbbVie.
    • This large cap growth stock is offering extremely cheap valuations in light of its earnings growth trajectory and the comparative valuation of the overall market.
  • My Predictions For 2015 - Part II
    Dec. 29, 2014 SPY, DIA, QQQ 57 Comments

    Summary

    • In the second of a three part series on predictions for the New Year, we will take a look at where the domestic economy and markets are headed in 2015.
    • The United States economy has the wind at its back as we enter the New Year and job & economic growth should remain robust in 2015.
    • Domestic markets should continue to benefit from being the best house in a bad neighborhood. Some ideas on what sectors to over and under weight in the coming 12 months.
  • Navidea Pharmaceuticals: An Update On My $2 Biotech Lottery Ticket
    Dec. 23, 2014 NAVB 57 Comments

    Summary

    • It seems time for an investment update on small biotech Navidea Pharmaceuticals given the stock's recent rally and positive developments at the company.
    • Navidea is expanding the geographical footprint of its main product Lymposeek and has made the decision to pursue therapeutic opportunities.
    • These are positive developments that could drive still substantial upside at this small speculative opportunity for aggressive growth investors in the biotech space.
  • My Predictions For 2015 - Part I
    Dec. 23, 2014 SPY, VGK, OIL 105 Comments

    Summary

    • With only a few more trading sessions left in 2014, it is the time of the year financial commentators offer up their predictions for the New Year.
    • This is the first of a three part series that will look at two macro trends that should continue, what's ahead for the market and some good stocks to own.
    • Today we look at why oil should end higher than its current levels and why the Eurozone will continue to show disappointing growth facilitating a further slide in the euro.
  • Oasis Petroleum: High Risk/High Reward Oil Play
    Dec. 22, 2014 OAS 21 Comments

    Summary

    • After three months of a deep consistent decline, the exploration & production sector finally had a significant surge in the market this week as oil prices started to stabilize.
    • Sometimes the best time to invest is when there is "blood in the streets". The E&P sector certainly qualifies. Encouragingly insiders are also increasing their purchases in this space recently.
    • One stock with recent insider activity is Bakken play Oasis Petroleum. Why I believe this energy concern will be a long term winner for patient investors is detailed below.
  • Gilead: What's Ahead In 2015 For This Biotech Juggernaut
    Dec. 20, 2014 GILD 438 Comments

    Summary

    • Biotech juggernaut Gilead Sciences has provided its shareholders with better than a 30% gain in 2014 so far as we head into the end of the year.
    • Although the stock has spent the last three months consolidating those gains in a relatively narrow trading range, the direction for 2015 remains up.
    • Gilead has several major positive catalysts on the horizon in 2015. Why I believe the stock will head much higher in the twelve months ahead is detailed below.
  • Micron: A Big Value Story Most Of The Market Is Missing
    Dec. 18, 2014 MU 60 Comments

    Summary

    • After a very solid first half of 2014, the stock of Micron has spent the last six months moving in a relatively narrow trading range consolidating first half gains.
    • However, core business fundamentals are improving, the stock is very cheap and earnings estimates continue to rise.
    • Why I believe the stock has 40% to 50% upside over the next 12 months is profiled below.
  • Procera Networks: A Cash Rich Small-Cap Gem To Consider
    Dec. 17, 2014 PKT 11 Comments

    Summary

    • Beaten down Procera Networks is rallying today on the announcement of some new orders and this could be the start of a significant rally in the stock.
    • The shares have had a tough year as the stock has been cut in half from earlier highs as revenue growth failed to materialize during the year.
    • However, the company has a cash rich balance sheet, activist funds are circling and positive catalysts are on the horizon. The environment is starting to look brighter for Procera.